首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Calmodulin phosphorylation and modulation of endothelial nitric oxide synthase catalysis
【24h】

Calmodulin phosphorylation and modulation of endothelial nitric oxide synthase catalysis

机译:钙调蛋白磷酸化和内皮一氧化氮合酶催化的调节

获取原文
获取原文并翻译 | 示例
       

摘要

The endothelial NO synthase (eNOS) is regulated by diverse protein kinase pathways, yet eNOS activity ultimately depends on the ubiquitous calcium regulatory protein calmodulin (CaM). In these studies, we establish that CaM itself undergoes phosphorylation in endothelial cells and that CaM phosphorylation attenuates eNOS activation. Using [~(32)P]orthophosphoric acid biosynthetic labeling, we found that CaM is a phosphoprotein in bovine aortic endothelial cells (BAEC) and that the kinase CK2 promotes CaM phosphorylation in BAEC. Phosphorylation of CaM by purified CK2 in vitro reduces the V_(max) of immunopurif led eNOS by a factor of 2 but has no effect on the K_A for CaM or calcium. Additionally, [~(32)P]orthophosphoric acid biosynthetic labeling of mutant CaM-transfected BAEC revealed that phosphorylation of Ser-81 to alanine mutant CaM ("phosphonull" S81A mutant) is dramatically reduced relative to WT, whereas phosphorylation of the "phosphomimetic" Ser-81 to aspartate (S81D) mutant is unchanged. Further studies using Escherichia coli-expressed and phenyl-Sepharose-purified CaM mutants revealed that the S81A mutation abrogates in vitro CK2-mediated phosphorylation of CaM, whereas phosphorylation of the S81D CaM mutant by CK2 is preserved. Additionally, we found that the phosphomimetic S101D CaM mutant is impaired in its ability to activate eNOS. Taken together, these results suggest that phosphorylation of CaM inhibits eNOS catalysis and proceeds in a hierarchical manner, initially requiring phosphorylation of the CaM Ser-81 residue. We conclude that CaM phosphorylation may represent a unique pathway in the regulation of eNOS signaling and thereby may play a role in modulating NO-dependent vascular responses.
机译:内皮NO合酶(eNOS)受多种蛋白激酶途径调节,但eNOS活性最终取决于普遍存在的钙调节蛋白钙调蛋白(CaM)。在这些研究中,我们确定CaM本身在内皮细胞中发生磷酸化,并且CaM磷酸化减弱eNOS激活。使用[〜(32)P]正磷酸生物合成标记,我们发现CaM是牛主动脉内皮细胞(BAEC)中的一种磷蛋白,并且激酶CK2促进了BAEC中CaM的磷酸化。体外纯化的CK2使CaM磷酸化,使免疫纯化的eNOS的V_(max)降低2倍,但对CaM或钙的K_A没有影响。另外,突变体CaM转染的BAEC的[〜(32)P]正磷酸生物合成标记显示,相对于野生型,Ser-81磷酸化为丙氨酸突变体CaM(“磷脂” S81A突变体)显着降低,而“拟磷酸酯”的磷酸化Ser-81转为天冬氨酸(S81D)突变体未改变。使用大肠杆菌表达的和经苯基琼脂糖纯化的CaM突变体的进一步研究表明,S81A突变消除了CK2介导的CaM的体外磷酸化,而S81D CaM突变体被CK2的磷酸化得以保留。此外,我们发现,模拟磷酸S101D CaM突变体的激活eNOS能力受损。综上所述,这些结果表明CaM的磷酸化抑制eNOS催化并以分级的方式进行,最初需要CaM Ser-81残基的磷酸化。我们得出结论,CaM磷酸化可能代表eNOS信号调节中的独特途径,从而可能在调节NO依赖性血管反应中发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号